Why some cancers and infections come back after T‑cell therapies
Defining the Mechanisms of Immune Escape After Adoptive T cell Therapies
['FUNDING_P01'] · FRED HUTCHINSON CANCER CENTER · NIH-11177694
Researchers are looking into how to stop leukemia relapse, life‑threatening infections, and severe immune side effects after bone marrow transplant and T‑cell therapies.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11177694 on ClinicalTrials.gov |
What this research studies
This project uses laboratory and mouse models that mimic bone marrow transplant, CAR T, and TCR transgenic T‑cell therapies to study relapse, graft‑versus‑host disease, cytokine release syndrome, and CMV reactivation. The team examines how newer transplant approaches—naïve T cell depletion and post‑transplant cyclophosphamide—change T cell exhaustion, stem‑like memory T cells, and NK cell responses in bone marrow. They are developing fully murine CAR T models of B‑cell leukemia and multiple myeloma to identify pathways that drive toxicity and immune escape. The researchers will test synthetic cytokines in these models to try to boost protective immunity against both leukemia and opportunistic infections.
Who could benefit from this research
Good fit: People with B‑cell leukemia or multiple myeloma who are receiving or may receive hematopoietic cell transplantation or CAR‑T/TCR T‑cell therapies would be the most relevant group.
Not a fit: Patients with unrelated solid tumors not treated with transplant or T‑cell therapies are unlikely to directly benefit from this project.
Why it matters
Potential benefit: If successful, this work could lead to ways to lower relapse, reduce severe immune toxicities, and prevent dangerous infections after transplant or T‑cell therapy.
How similar studies have performed: Clinical tools like CAR‑T and post‑transplant cyclophosphamide have helped many patients, but relapse, immune toxicity, and CMV remain common problems and this work builds on promising preclinical findings.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HILL, GEOFFREY ROGER — FRED HUTCHINSON CANCER CENTER
- Study coordinator: HILL, GEOFFREY ROGER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.